Glycan and glycosaminoglycans as clinical biomarkers and therapeutics. Part B (Livre numérique, 2019) [WorldCat.org]
aller au contenu
Glycan and glycosaminoglycans as clinical biomarkers and therapeutics. Part B Aperçu de cet ouvrage
FermerAperçu de cet ouvrage
Vérification...

Glycan and glycosaminoglycans as clinical biomarkers and therapeutics. Part B

Auteur : Lijuan Zhang
Éditeur: Cambridge : Academic Press, 2019.
Collection: Progress in molecular biology and translational science, v. 163.
Édition/format:   Livre numérique : Document : AnglaisVoir toutes les éditions et tous les formats
Résumé:
Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B, Volume 163 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include an Overview of Fugal Glycan-based Therapeutics, Heparin: An Essential Drug for  Lire la suite...
Évaluation:

(pas encore évalué) 0 avec des critiques - Soyez le premier.

Sujets
Plus comme ceci

Trouver un exemplaire en ligne

Trouver un exemplaire dans la bibliothèque

&AllPage.SpinnerRetrieving; Recherche de bibliothèques qui possèdent cet ouvrage...

Détails

Genre/forme: Electronic books
Format – détails additionnels: Print version:
(OCoLC)1052874139
Type d’ouvrage: Document, Ressource Internet
Type de document: Ressource Internet, Fichier d'ordinateur
Tous les auteurs / collaborateurs: Lijuan Zhang
ISBN: 9780128177396 012817739X 9780128177419 0128177411
Numéro OCLC: 1090925584
Notes: Includes index.
Description: 1 online resource
Contenu: Front Cover; Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics --
Part B; Copyright; Contents; Contributors; Preface; Chapter One: Heparin: An essential drug for modern medicine; 1. Introduction; 2. Structure of heparin; 3. The mechanisms of the heparin; 4. Clinical studies of heparin; 4.1. Anti-coagulation activity of heparin; 4.2. Anti-cancer activity of heparin; 4.3. Heparin in inflammatory diseases; 4.4. Heparin in infectious disease; 4.5. Other diseases; 5. Concluding remarks; Acknowledgments; References Chapter Two: Low molecular weight heparins and their clinical applications1. Introduction; 2. Structure of LMWHs; 3. Clinical uses of LMWHs; 4. Update on the LMWHs under clinic trials and its potential applications; 4.1. Anti-tumor; 4.2. Anti-viral; 4.3. Anti-inflammation; 4.4. Anti-diabetes-associated complications; 4.5. Other applications; 5. Concluding remarks; Acknowledgments; References; Chapter Three: The clinical use of Fondaparinux: A synthetic heparin pentasaccharide; 1. Structure and mechanism of Fondaparinux; 2. Pharmacokinetics and pharmacodynamics of Fondaparinux 3. Clinical application of Fondaparinux3.1. Prophylaxis of VTE; 3.2. Prophylaxis of DVT; 3.3. Other clinical indications; 4. Concluding remarks; Acknowledgments; Conflict of interest; References; Chapter Four: Heparinoids Danaparoid and Sulodexide as clinically used drugs; 1. Heparin and heparinoids; 2. Heparin, low molecular weight heparin, Danaparoid and Sulodexide; 3. Clinical applications of Danaparoid; 3.1. Danaparoid in HIT; 3.2. Danaparoid in DVT; 3.3. Danaparoid in DIC; 4. Clinical applications of Sulodexide; 4.1. Anticoagulant and antithrombotic activity 4.2. Prevention of reperfusion injury4.3. Sulodexide in other diseases; 5. Concluding remarks; Acknowledgments; References; Chapter Five: Efficacy of heparinoid PSS in treating cardiovascular diseases and beyond-A review of 31 years clinical exp ... ; 1. Introduction; 2. Preparation, chemical structure, and clinical doses; 3. Clinical uses and efficacy; 4. Adverse reactions; 5. Pharmacodynamics; 6. Pharmacokinetics; 7. Future perspectives; Acknowledgment; Conflicts of interest; References; Chapter Six: Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies 1. Introduction2. Preparation and structure of fucoidan; 3. Pharmacology and mechanism of fucoidan; 3.1. Chronic renal failure (CRF); 3.2. Acute kidney injury (AKI); 3.3. Diabetic nephropathy (DN); 4. Clinical uses and efficacy of fucoidan; 5. Future perspectives; Acknowledgments; References; Chapter Seven: Marine glycan-derived therapeutics in China; 1. Introduction; 2. Fucoidan (Haikunshenxi capsules); 2.1. Chemical structure and preparation; 2.2. Pharmacological activities; 2.3. Clinical applications; 3. Chitin ester (PS916); 3.1. Pharmacological activities; 3.2. Pharmacokinetics
Titre de collection: Progress in molecular biology and translational science, v. 163.
Responsabilité: edited by Lijuan Zhang.

Résumé:

Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B, Volume 163 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include an Overview of Fugal Glycan-based Therapeutics, Heparin: An Essential Drug for Modern Medicine, Low Molecular Weight Heparins and Their Clinical Applications, The Clinical Use of Fondaparinux: A Synthetic Heparin Pentasaccharid, Heparinoids as Clinically Used Drugs, Marine Glycan-Derived Therapeutics in China, Efficacy of Heparinoid PSS in Treating Cardiovascular and other Diseases-30 Years Clinical Applications in China, and more.

Critiques

Critiques d’utilisateurs
Récupération des critiques de GoodReads...
Récuperation des critiques DOGObooks…

Marqueurs

Soyez le premier.
Confirmez cette demande

Vous avez peut-être déjà demandé cet ouvrage. Veuillez sélectionner OK si vous voulez poursuivre avec cette demande quand même.

Fermer la fenêtre

Veuillez vous identifier dans WorldCat 

Vous n’avez pas de compte? Vous pouvez facilement créer un compte gratuit.